Abstracts tagged "rheumatoid arthritis"

Abstract Number: 0178 • ACR Convergence 2021
Abdominal Obesity May Confound Accuracy of Cardiovascular Risk Prediction in Rheumatoid Arthritis; Can Coronary Atherosclerosis Imaging and Biomarkers Help?
George Karpouzas¹, sarah ormseth², Elizabeth Hernandez² and Matthew Budoff³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, ³Division of Cardiology, and the Lundquist Institute ay Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: Accurate cardiovascular risk stratification is essential in rheumatoid arthritis (RA) care. Previous studies evaluated the impact of obesity (defined as body mass index) on…
Abstract Number: 0275 • ACR Convergence 2021
Impact of Disease Activity on Left Ventricular Diastolic Dysfunction in Rheumatoid Arthritis Patients
Natalia Guajardo-Jauregui, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Alejandra Rodriguez-Romero, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Catalina Andrade-Vazquez and Alan De Leon-Yañez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Cardiovascular disease (CVD) is the main cause of mortality in patients with rheumatoid arthritis (RA) reflected by a higher prevalence of cardiovascular risk factors…
Abstract Number: 0293 • ACR Convergence 2021
Increased Prevalence of Scleroderma Specific Autoantibodies in Seropositive Rheumatoid Arthritis with Lung Involvement
Vasiliki Koulouri¹, Kyriaki Tavernaraki², Mayra Giannelou³ and Clio Mavragani¹, ¹National and Kapodistrian University of Athens, Athens, Greece, ²Imaging and Interventional Radiology, Sotiria General and Chest Diseases Hospital, Athens, Greece, ³Department of Rheumatology, General Hospital of Athens "G. Gennimatas", Athens, Greece
Background/Purpose: To evaluate the prevalence of scleroderma (SSc) specific and anti-Ro52 autoantibodies in seropositive rheumatoid arthritis (RA) patients with lung involvement.Methods: Sera from 67 seropositive…
Abstract Number: 0494 • ACR Convergence 2021
The Distribution of Social Deprivation, Distance to Care and Disease Burden in Rheumatoid Arthritis Patients in the United States
Sharon Dowell¹, Huifeng Yun², Jeffrey Curtis³, Lang Chen⁴, Manuela Pedra-Nobre⁵, Dianne Wollaston⁶, SAWSAN NAJMEY⁷, Cynthia Lawrence-Elliott⁸, Theresa Lawrence-Ford⁹, Heather North¹⁰, Robin Dore¹¹, Soha Dolatabadi¹², Thaila Ramanujam¹³, Anne Winkler¹⁴, Stacy Kennedy¹⁵, Stephanie Ott¹⁶, Stephanie Ledbetter¹⁷, Grace Wright¹⁸ and Gail Kerr¹⁹, ¹Howard University College of Medicine, Washington, DC, ²University of Alabama Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama, Birmingham, AL, ⁵North Jersey Rheum. Center, Westfield, NJ, ⁶Memorial Advanced Rheumatology, Houston, TX, ⁷Midstate Rheumatology Center, PA, Freehold, NJ, ⁸North Georgia Rheum Group, Atlanta, GA, ⁹North Georgia Rheum Group, Atlanta, MD, ¹⁰Pardee UNC, Hendersonville, NC, ¹¹Robin K. Dore, MD Inc, Tustin, CA, ¹²Soha Dolatabadi, MD, Los Angeles, CA, ¹³Santa Cruz Rheumatology, Inc., Santa Cruz, CA, ¹⁴Winkler Medical Practice, Springfield, MO, ¹⁵Rowan Diagnostic Clinic, Concord, NC, ¹⁶Fairfield Medical Center, Carroll, OH, ¹⁷University of Alabama at Birmingham, Birmingham, AL, ¹⁸Grace C Wright MD PC, and Association of Women in Rheumatology, New York, NY, ¹⁹Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC
Background/Purpose: The overall success of RA therapy is dependent on access to specialty care, insurance coverage and effective management of associated comorbidities. Whether RA disease…
Abstract Number: 0574 • ACR Convergence 2021
Prevalence and Early Progression of Lung Diseases in Patients with Recently-Diagnosed Rheumatoid Arthritis: A Prospective Cohort Study
Tina Mahajan¹, Daniel Hershberger¹, Matt Devries², Punyasha Roul¹, Yangyuna Yang¹, Sherrie Edwards¹, Geoffrey Thiele¹, Ted Mikuls¹, James O'Dell¹ and Bryant England¹, ¹University of Nebraska Medical Center, Omaha, NE, ²University of Nebraska Medical Center, Omaha
Background/Purpose: Several types of lung diseases complicate the rheumatoid arthritis (RA) disease course such as interstitial lung disease (ILD) and obstructive lung diseases. The prevalence…
Abstract Number: 0605 • ACR Convergence 2021
Impact of Area of Residence on Perceptions of Health and Disease Activity in Ethnic Minorities with Rheumatoid Arthritis in an Urban Setting
Mohamed Jalloh¹, Sharon Dowell², Richard Ogunti¹ and Gail Kerr³, ¹Howard University Internal Medicine Residency, Washington, DC, ²Howard University College of Medicine, Washington, DC, ³Washington D.C., Veterans Affairs Medical Center (VAMC)/Georgetown and Howard Universities, Washington, DC
Background/Purpose: Health care disparities in hypertension and other chronic disease are well established. Ethnic minority residents of Washington DC, particularly Wards 7 and 8, have…
Abstract Number: 0759 • ACR Convergence 2021
The Patient as Assessor of Disease Status: A Graphical Evaluation of Relations Between Patient-Reported Outcomes in Early Rheumatoid Arthritis
Diederik De Cock¹, Gert Verhavert¹, Sofia Pazmino¹, Delphine Bertrand¹, Michal Doumen¹, Rene Westhovens² and Patrick Verschueren³, ¹KU Leuven, Leuven, Belgium, ²University Hospitals KU Leuven, Maaseik, Belgium, ³University Hospitals Leuven - KULeuven, Leuven, Belgium
Background/Purpose: Current EULAR-guidelines recommend treating Rheumatoid Arthritis (RA) early, intensively and to-target. Patient-Reported Outcomes (PROs) can be important contributors for remote monitoring of disease status…
Abstract Number: 0800 • ACR Convergence 2021
Digital Spatial Profiling Reveals Distinct Synovial Tissue Transcriptomic Signature of Sustained Disease Remission in Rheumatoid Arthritis Patients at Risk of Disease Flare After Treatment Tapering or Discontinuation
Stefano Alivernini¹, Simone Perniola², Marco Gessi³, Maria Rita Gigante⁴, Clara Di Mario⁵, Luca Petricca⁴, Dario Bruno⁵, Laura Bui¹, Annamaria Paglionico¹, Valentina Varriano¹, Maria Antonietta D'Agostino⁶, Barbara Tolusso¹ and Elisa Gremese⁷, ¹Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ²Fondazione Policlinico Universitario A. Gemelli IRCCS - University of Verona, Santeramo in Colle, Italy, ³Fondazione PoliclinicoUniversitario A. Gemelli IRCCS, Rome, Italy, ⁴Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, ⁵Division of Rheumatology, Università Cattolica del Sacro Cuore, Rome, Italy, ⁶Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, ⁷Division of Rheumatology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy
Background/Purpose: Sustained disease remission is the treatment goal for Rheumatoid Arthritis (RA) leading patients to be eligible to treatment tapering or discontinuation. However, disease flare…
Abstract Number: 0818 • ACR Convergence 2021
Biologics Initiation in Moderate vs Severe Rheumatoid Arthritis Patients: Prospective Observational Study from a Canadian Registry
Nancy Guo¹, Xiuying Li², Mohammad Movahedi³, Angela Cesta⁴ and Claire Bombardier⁵, ¹Kingston General Hospital, Kingston, ON, Canada, ²OBRI at University Health Network, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Toronto General Hospital Research Institute, UHN, Toronto, ON, Canada, ⁵University of Toronto - Toronto, Toronto, ON, Canada
Background/Purpose: Prior studies have shown that in the real-world setting, rheumatoid arthritis (RA) patients have lower disease activity than those studied in clinical trials. However,…
Abstract Number: 0835 • ACR Convergence 2021
Immunogenicity of Rituximab Biosimilar GP2013 in Chronic Inflammatory Rheumatic Disorders in Daily Clinical Practice
Jerome Avouac¹, Rodolphe Cougnaud-Murail¹, Claire Goulvestre², Sophie Dumas³, Anna Molto⁴, Corinne Miceli-Richard⁵, ornella conort³, Frederic Batteux² and Yannick Allanore¹, ¹Université de Paris, Service de Rhumatologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ²Université de Paris, Service d'Immunologie, Hôpital Cochin, AP-HP.CUP, Paris, France, ³Université de Paris, Service de pharmacie, Hôpital Cochin, AP-HP.CUP, Paris, France, ⁴Department of Rheumatology, University of Paris, Cochin Hospital, Paris, France, ⁵Assistance Publique Hpitaux de PAris, Paris, France
Background/Purpose: To study in daily practice the risk of immunogenicity of patients treated with rituximab (RTX) biosimilar GP2013 for their chronic inflammatory rheumatic disorder.Methods: A…
Abstract Number: 0969 • ACR Convergence 2021
Loss of Balance Between Protective and Pro-inflammatory Synovial Tissue T Cell Polyfunctionality Predates Clinical Onset of Rheumatoid Arthritis
Achilleas Floudas¹, Nuno Neto², Carl Orr³, Mary Canavan⁴, Phil Gallagher³, Conor Hurson⁵, Michael Monaghan², Nagpar Sunil⁶, Ronan Mullan⁷, Douglas Veale⁸ and Ursula Fearon², ¹Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Ireland, ²Trinity College Dublin, Dublin, Ireland, ³St Vincent's Hospital, Dublin, Ireland, ⁴Trinity College, Santry, Ireland, ⁵St Vincents University Hospital, Dublin, Ireland, ⁶Janssen R&D, Spring House, PA, ⁷Tallaght University Hospital, Dublin, Ireland, ⁸University College Dublin, Dublin, Ireland
Background/Purpose: Effective treatment of Rheumatoid arthritis (RA) patients is achievable within a short window of opportunity. T-cells are early drivers of synovial inflammation of RA,…
Abstract Number: 1021 • ACR Convergence 2021
Organic Dust Exposure Induces Post-translational Protein Modifications and a HLA-DR4-dependent Pro-inflammatory Lung Phenotype in a Murine Model of Interstitial Lung Disease
Jill Poole¹, Ted Mikuls¹, Amy Nelson¹, Rohit Gaurav¹, Michael Duryee¹, Geoffrey Thiele¹, Bryant England¹ and Dana Ascherman², ¹University of Nebraska Medical Center, Omaha, NE, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Environmental and occupational exposures have been epidemiologically linked to the development of rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Previous investigation and modeling have also…
Abstract Number: 1167 • ACR Convergence 2021
Rheumatoid Arthritis Patients’ Treatment Goals Relate to Disease Activity and Rheumatology Experiences
Kelly O'Neill¹, Pamela Sinicrope², Kathryne Marks³, Elena Myasoedova², Cynthia Crowson⁴ and John Davis², ¹Rheumatoid Patient Foundation, Lutz, FL, ²Mayo Clinic, Rochester, MN, ³Rheumatoid Patient Foundation, Boston, MA, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: Shared decision making and treat to target are recognized guidelines to treat Rheumatoid Arthritis (RA). We previously reported associations of shared treatment goal discussions…
Abstract Number: 1211 • ACR Convergence 2021
Evaluation of the Cervical Involvement Frequency and Associated Risk Factors in Patients with Rheumatoid Arthritis
Gulay Alp¹, Haluk Cinaklı¹, Dilek Solmaz², Eda OTMAN¹, Elif Ediboglu¹, Esra Erpek¹ and Servet Akar², ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey
Background/Purpose: Spinal involvement in Rheumatoid arthritis (RA) is limited to the upper region of the cervical spine which leads to cervical spine instability (CSI); anterior…
Abstract Number: 1227 • ACR Convergence 2021
Clinical Predictors of Response to Methotrexate in Patients with Rheumatoid Arthritis: A Machine Learning Approach Using Clinical Trial Data
Stephanie Duong¹, Cynthia Crowson², Elizabeth Atkinson¹, Arjun Athreya¹, John Davis¹, Eric Matteson³, Richard Weinshilboum¹, Liewei Wang¹ and Elena Myasoedova¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: Methotrexate (MTX) is the preferred initial disease-modifying drug (DMARD) for rheumatoid arthritis (RA). However, up to 50% of patients respond inadequately to MTX. Clinically…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.